Week 5 is where the cut stops being a calorie-deficit story and starts being a body-composition story. The Phase 1 stack stripped weight. Phase 2 decides what gets stripped — fat or muscle — and where that fat comes from. The lever you pull starting Monday of Week 5 is the GH axis: Tesamorelin in the evening, Ipamorelin pre-bed, and a non-negotiable fasted window that protects the pulse from being blunted by circulating insulin.
What the GH layer actually does to your cut
Growth hormone is the only endogenous signal that does three things simultaneously: spares lean mass under caloric restriction, mobilizes lipid from visceral depots, and improves overnight tissue repair. The practitioner corpus is consistent on this — when a cut runs past four weeks on GLP-1 mono-therapy, the lean-mass attrition curve steepens. Adding GH-axis support flattens it.
Tesamorelin is the workhorse here. It's a GHRH analog with a single, narrow clinical claim that matters for cutters: it is the only GH secretagogue with FDA approval specifically for visceral adipose tissue reduction. The mechanism is upstream — it stimulates the pituitary to release endogenous GH in a physiologic pulse, preserving the feedback loop. That endogenous pulse then drives IGF-1 from the liver, which mediates the lipolytic and anabolic downstream effects. Practitioner consensus is that visceral fat — the deep abdominal fat that surrounds organs — is the tissue most responsive to a Tesamorelin-driven GH rise, far more so than subcutaneous fat. If your stubborn fat reads on the DEXA scan as android-pattern visceral, this is the compound that addresses it.
Ipamorelin runs on a different mechanism: it's a GHRP — a ghrelin-mimetic that pulses GH through a separate pituitary pathway and suppresses somatostatin, which would otherwise put a ceiling on GH output. Pair a GHRH (Tesamorelin) with a GHRP (Ipamorelin) and the combined output exceeds what either compound produces alone — the two pathways are additive, not redundant. Ipamorelin is the cleanest GHRP available: no cortisol spillover, no prolactin spike, no appetite stimulation worth mentioning at protocol doses. That matters during a cut, where elevated cortisol would erase the lean-sparing benefit you're paying for.
CJC-1295 without DAC (Modified GRF 1-29) is the GHRH some practitioners prefer over Tesamorelin for cost reasons — it does similar work but lacks the visceral-fat-specific clinical data. The DAC version (CJC-1295 with the Drug Affinity Complex) is not the protocol of choice here: the practitioner corpus flags it as limited to four to five weeks per cycle to avoid pituitary damage. Stick with the no-DAC version if you substitute, or use Tesamorelin directly.
The food window rule (this is the single thing most people get wrong)
GH and insulin are antagonistic signals. The same molecule cannot be high simultaneously — when insulin is elevated, the GH pulse collapses. The corpus is unambiguous: Ipamorelin and any GHRP/GHRH stack must be injected on an empty stomach, at least 90 minutes after the last meal, and ideally with no food for 30 minutes afterward. Pre-bed dosing works because by 10-11 PM most cutters are already 2+ hours post-dinner and entering the overnight fasted window. Inject too close to a meal and you wasted the dose — the pulse will be flat.
A second constraint matters more during a cut than during a bulk: GH transiently worsens insulin sensitivity. The corpus flags this directly — secretagogues like Ipamorelin, CJC-1295, and Tesamorelin can push fasting glucose up. If your baseline insulin from the Phase 1 bloodwork was already elevated, this stack pushes you further into metabolic dysfunction before it pulls you out. Track fasting glucose weekly during weeks 5-10. If it climbs above 100 mg/dL and stays, the protocol needs adjustment, not continuation.
The Phase 2 stack
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| Tesamorelin | 1 mg | SubQ | Evening, 5 days on / 2 days off | 🔵 Clinical | 8-10 week cycle, then 8-10 weeks off. Inject ≥2 hrs after last meal. Visceral-fat targeted. |
| Ipamorelin | 200-500 mcg | SubQ | Pre-bed, fasted | 🟢 Expert | Can co-inject with Tesamorelin if timing aligns. Empty stomach ≥90 min post-meal, no food 30 min after. |
| CJC-1295 (no DAC / Mod GRF 1-29) | 100 mcg | SubQ | Pre-bed, fasted (only if substituting for Tesamorelin) | 🟢 Expert | Use as Tesamorelin alternative, not addition. Avoid DAC version — pituitary risk past 4-5 weeks. |
| Continuing Phase 1 GLP-1 (Semaglutide / Tirzepatide / Retatrutide) | Maintenance dose per Phase 1 titration | SubQ | 1x/week | 🔵 Clinical | Do not increase further in Phase 2. Find the minimum dose that keeps fat loss moving. |
| MOTS-c | [practitioner corpus thin on cut-phase MOTS-c protocol — track and report] | — | — | 🟣 Experimental | Mentioned in mentor stacks for mitochondrial fat oxidation support; protocol specifics not anchored in substrate. |
The two-injection day looks like this: morning is your GLP-1 day (once weekly), nothing else. Evening, ~10 PM, two hours after dinner, in the abdomen-near subcutaneous tissue: 1 mg Tesamorelin in one site, 200-500 mcg Ipamorelin in an adjacent site. Rotate sites left/right of the umbilicus across the week. Five days on, two days off — most practitioners run Mon-Fri on, weekend off. The two-day break preserves pituitary responsiveness.
What you should feel
- Week 5-6: Sleep deepens noticeably within 5-7 nights. The Ipamorelin pulse synergizes with the natural slow-wave GH surge — REM and delta-wave architecture improve. Morning grogginess drops. This is the earliest signal the dose is working.
- Week 6-7: Skin quality changes — better hydration, faster minor-cut healing. Recovery from training feels disproportionate to the calorie deficit you're still running.
- Week 7-8: Visceral waist measurement starts dropping independently of total bodyweight. DEXA at week 8 (if pulled) will show android fat declining faster than gynoid.
- Week 8-10: Body composition diverges from the scale. Bodyweight may plateau while waist circumference and visceral readings keep falling. This is the protocol working — do not respond by cutting calories further.
What's NOT happening yet
- You are not building muscle. This is a cut. The GH layer is sparing lean mass, not adding to it. Strength may hold or creep slightly; cross-sectional area will not grow under a deficit.
- Total scale weight loss does not accelerate. Tesamorelin is a body-composition tool, not a weight-loss tool. The benefit shows in DEXA, waist tape, and mirror — not the scale.
- Fasting glucose may rise 5-15 mg/dL. This is expected with GH-axis stimulation. It is not a failure of the protocol. It is a signal to monitor weekly and intervene only if it climbs above 100 mg/dL sustained.
- IGF-1 will rise — and it should. Mid-cycle bloodwork around week 8 should show IGF-1 elevated above baseline but ideally within the upper-quartile of the age-adjusted reference range, not above it. If IGF-1 exceeds the top of the reference range, drop the Tesamorelin dose.
- You are not "on HGH." This protocol stimulates endogenous GH release in physiologic pulses. It does not replicate the supraphysiologic flatline of exogenous somatropin. The safety profile and the results are different — and the substrate is clear that the secretagogue path preserves the feedback loop where exogenous HGH does not.
Research describes this pattern. Track the glucose, track the visceral tape, track the sleep — and adjust the dose to the response, not to the protocol.